Online Comments to the Pharmaceutical Benefits Advisory Committee

9 February 2015
Consumer submissions can make all the difference to the registration of life-saving drugs for melanoma. You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March. We are encouraging everyone to have a voice and get involved in helping register the anti-PD1 drug.
If you would like to make a submission please complete the online submission form or email your submission directly to the PBAC. Submissions close on the 11th of February, 2015.
To find out more information visit the PBAC website.

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019
This week, Melanoma Institute Australia hosted the first of six

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
Federal government urged

Team Melanoma smashes City2Surf
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!

Ready to run over melanoma at City2Surf 2019
Lauren O'Brien tells us why she's running for a cause close to her heart

Community Fundraising July Wrap-Up
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in

Breast cancer drug may hold key to tackling most deadly type of melanoma
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a

MIA takes centre stage at leading cancer conference
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma

International Clinical Trials Day 2019
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.

Emma Betts' legacy will live on
“I’m the age Emma was when she passed away. It almost feels

Support PBS listing for three adjuvant treatments of resected Stage III melanoma
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions

Support PBS listing for pembrolizumab
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.

How are the Premier's Awards helping cancer researchers?
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.

Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.

Making a difference to many
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.

Aussie icon Sophie Monk calls on Australians to get behind Melanoma March
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.

Melanoma breakthrough paves way for personalised treatment for all cancer patients
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.

Melanoma March announces 2019 Principal Partner
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!

Swimming champion Cate Campbell spearheads national campaign to save lives from melanoma
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.

MIA experts collaborate on groundbreaking research
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.

World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.